Clinical Trial Update: CT-95 in Advanced Cancers Associated With Mesothelin Expression [Phase 1]

View source ↗

Summary

Phase 1 trial CT-95 for mesothelin-expressing tumors is currently recruiting across multiple indications, including epithelial ovarian cancer and mesothelioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Colorectal Cancer
• Epithelial Ovarian Cancer
• Malignant Peritoneal Mesothelioma
• Malignant Pleural Mesothelioma
• Non-small Cell Lung Cancer
• Pancreatic Adenocarcinoma

Drugs mentioned

• CT-95

Snippet

Sponsor: Context Therapeutics Inc. | Conditions: Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer | Phase 1 | Status: RECRUITING